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Abstract
Background: We aimed to explore whether monocyte to lymphocyte ratio (MLR) provides predictive value of the
lesion severity in patients with coronary artery disease (CAD).
Methods: Five hundred forty-three patients undergoing coronary angiography were analyzed in this retrospective
study. Patients with coronary stenosis were divided into three groups on the basis of Syntax score. The control
group consisted of patients with normal coronary arteries. MLR was calculated by dividing monocytes count by
lymphocytes count obtained from routine blood examination. Multivariate logistic analysis was used to assess risk
factors of CAD. Ordinal logistic regression analysis was used to assess the relationship between MLR and the lesion
severity of coronary arteries.
Results: MLR was found to be an independent risk factor of the presence of CAD (OR: 3.94, 95% CI: 1.20–12.95)
and a predictor of the lesion severity (OR: 2.05, 95% CI: 1.15–3.66). Besides, MLR was positively correlated with
Syntax score(r = 0.437, p < 0.001). In the receiver-operating characteristic (ROC) curve analysis, MLR, with an optimal
cut-off value of 0.25, predicted the severe coronary lesion with a sensitivity of 60.26% and specificity of 78.49%.
Conclusions: MLR was an independent risk factor of the presence of CAD, and a predictor of the lesion severity.
Compared to neutrophil to lymphocyte ratio (NLR), MLR has better performance to reflect the severity of coronary
lesion.
Keywords: Monocyte to lymphocyte ratio, Coronary artery disease, Syntax score
Background
CAD is still a major contributor of mortality in patients
with cardiovascular diseases, although much effort has
been made to improve disease management including
intensive medical care and invasive procedures over the
last decade [1–5]. The severity of coronary lesion is still
a crucial factor in the stratification of cardiovascular risk
to determine the optimal treatment strategy. Several
randomized Syntax trials have released the results that
Syntax Score system, could be applied as a grading
method to determine risk level, taking into account:
number of disease segments, tortuosity, calcification,
presence of thrombus, lesion length, dominance, bifur-
cation, trifurcation, aorto-ostial lesions, diffuse disease,
and total occlusion, and each coronary lesion with a diam-
eter stenosis ≥ 50% in vessels ≥ 1.5 mm was scored [6–8].
As a major contributor on the initiation and aggrava-
tion of atherosclerosis, inflammation, regulated by im-
mune cells, could accelerate atherosclerotic progression,
ultimately causing plaque rupture and serious adverse
events related to CAD [9, 10]. The existence of inflam-
matory cells, such as monocytes, macrophages, dendritic
cells and T cells, is a common characteristic in forma-
tion of atherosclerotic lesions [11–13]. In addition,
immune cells, cytokines and other biomedical markers
implicated in inflammatory response have been inves-
tigated to predict progression/severity of the lesion
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Increased values of white blood cells and subtypes,
such as eosinophils, monocytes, neutrophils, and lym-
phocytes, have been found to be closely related with the
cardiovascular adverse events [15, 16]. NLR and MLR
are novel indicators of baseline inflammatory response.
NLR has been reported to be an independent factor of
clinical outcomes in coronary artery disease, and an at-
tractive biomarker for predicting the severity of the le-
sion, which has potential to be a universal biomarker in
clinical applications [17–20]. MLR has been proved to
be a prognostic factor in patients with malignancies and
tuberculosis [21–24]. However, the role of MLR in CAD
is still unknown. Therefore, we designed this study to in-
vestigate whether MLR is an independent risk factor of
CAD, and could be useful for patient risk-stratify. To the
best of our knowledge, this is the first report on the rela-
tionship between MLR and CAD.
Methods
Study population
Five hundred forty-three participants who underwent
coronary angiography for suspected or known coronary
atherosclerosis at the Civil Aviation General Hospital
were retrospectively analyzed in the project between
January 2014 and August 2015. The study protocol was
approved by the Ethical Committee of Civil Aviation
General Hospital, and informed consent was obtained
from all patients enrolled. Exclusion criteria were con-
genital heart disease, valvular heart disease, severe heart
failure, hematonosis, liver or renal dysfunction, stroke,
tumor, thyroid disease, autoimmune disease and infec-
tious diseases. Enrolled patients underwent clinical in-
vestigation for systematic evaluation of cardiac function
and were requested for the information of family history
of CAD and history of smoking, previous CAD, hyper-
tension, diabetes and non-heart diseases. The diagnosis
of CAD was based on current AHA/ACC guidelines
[25]. Hypertension was defined as systolic blood pres-
sured ≥140 mmHg and/or a diastolic blood pressure ≥
90 mmHg taken from at least two-times, or current use
of an antihypertensive medication. Diabetes mellitus was
defined as fasting plasma glucose level ≥7.0 mmol/l or
casual plasma glucose level ≥ 11.1 mmol/l or active use
of an antidiabetic agent.
Laboratory analysis
Venous blood samples of all patients were drawn from
upper limb. Patients were advised to fast at least for 12 h
before blood investigations. The blood routine and bio-
chemical indicators were measured by clinical laboratory
of our hospital. The biochemical indicators included fast-
ing blood-glucose (FBG), total cholesterol (TC), triglycer-
ides (TG), low density lipoprotein cholesterol (LDL), high
density lipoprotein cholesterol (HDL), serum creatinine
(SCr) and uric acid (UA). The biochemical indicators
were determined by an automatic biochemical analyzer
(Beckman Coulter, CA, USA).
Assessment of the severity of CAD
Coronary angiogram was assessed by two interventional
physicians blindly. The CAD was defined as the exist-
ence of significant narrowing (≥50%) in any of the main
coronary arteries, according to coronary artery lesion
classification of AHA/ACC. Coronary artery of the con-
trol group in the study was defined by the presence of
< 50% stenoses.
Diagnostic angiograms were scored based on the
Syntax Score. Syntax score is a relatively mature evalu-
ation system to reflect the coronary stenosis prospect-
ively. Georgios et al have reported the full details on
Syntax score calculation [7]. Additionally, CAD patients
were divided into three groups based on the Syntax
score (mild =1–22, moderate 23–32, and severe ≥ 33).
Statistical analysis
Continuous variables were defined as mean ± SD or
median (interquartile range); categorical variables were
expressed as percentages. For continuous variables, the
Kolmogorov-Smirnov test was applied to test the nor-
mality of distribution, t test or the Mann-Whitney U
test, one-way ANOVA model was used to compare. For
categorical variables, the chi-square test was used.
Spearman rank test was used to test correlations. ROC
curve analysis was performed to verify the diagnostic
accuracy of MLR level in the presence and severity of
CAD. Binary and ordinal logistic regression analysis
was used to assess the independent predictors of CAD
and coronary lesion severity respectively. Statistical
analyses were performed using SPSS 15.0. A statistically
significance was taken as a 2-tailed p < 0.05.
Results
Baseline characteristics of the study population
Baseline demographic and biochemical characteristics of
all 543 patients were outlined in Table 1. Study subjects
consisted of 381 patients with CAD (CAD group, 55%
male: age 63 ± 10 years) and 162 patients with normal
artery conditions (control group, 35% male: age 55 ±
9 years). Patients with CAD were a bit older, and had
more conventional CAD risk factors. The level of fasting
blood glucose and creatinine were higher in CAD group.
Compared to the control group, patients with CAD
showed a higher leukocyte, neutrophil and monocyte
counts and lower lymphocyte counts. NLR and MLR
were higher in CAD group.
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MLR is the independent risk factor of the presence of CAD
Multivariate logistic analysis was used to assess 15 clinico-
pathological characteristics: age, gender, smoking, hyper-
tension, diabetes, fasting blood glucose, HDL, creatinine,
leukocyte, neutrophil, monocyte, lymphocyte, platelet,
NLR and MLR. Results showed in Table 2 demonstrated
that MLR (OR: 3.94, 95% CI: 1.20–12.95) was the
independent risk factor of CAD, together with age, male,
hypertension, fasting blood glucose and NLR.
The efficiency of MLR in detecting CAD
ROC curve analysis was applied to test the efficiency of
MLR in detecting CAD with an AUC of 0.727 (95% CI:
0.683–0.771), Fig. 1b. With a cut-off level of 0.18, MLR
predicted CAD with a sensitivity of 69.03% and specifi-
city of 64.81%.
Baseline characteristics of the study population based on
coronary atherosclerosis severity
On the basis of Syntax score to assess coronary athero-
sclerosis severity, 382 CAD patients were divided into
three groups (Syntax score: mild =1–22, moderate 23–
32, and severe ≥ 33). The control group consisted of
162 patients with normal coronary arteries, the same as
mentioned in Table 1. The distribution of patients’ clinico-
pathological characteristics were presented in Table 3.
Significant differences between severity of coronary
atherosclerosis and age, gender, smoking, hypertension,
diabetes, fasting blood glucose, creatinine, leukocyte, neu-
trophil, monocyte, lymphocyte, NLR and MLR were
demonstrated. The MLR level in severe atherosclerosis
group was statistically higher than that of other three
groups (p < 0.001, Fig. 2).
MLR is the independent predictor of the lesion severity in
CAD
An ordinal multivariate logistic regression was carried
out to investigate which factors could be favorable for
predicting the severity of the lesion.. The regression re-
sult in Table 4 demonstrated that age, smoking, diabetes,
hypertension, fasting blood glucose and MLR were inde-
pendent predictors for the severity of coronary lesion.
MLR was an independent predictor of the coronary le-
sion severity (OR: 2.05, 95%CI: 1.15–3.66), while NLR
was not. In the correlation analysis, MLR has significant
association with the Syntax score (r = 0.437, p < 0.001,
Fig. 1a).
The diagnostic efficiency of MLR in detecting the severe
coronary lesion
ROC curve was used to analysis the efficiency of MLR in
detecting the severe coronary lesion based on Syntax
score. A cut-off point of 0.25 for MLR predicted severe
coronary lesion with a sensitivity of 60.26% and specifi-
city of 78.49% (ROC area under curve: 0.761, 95% CI:
0.702–0.820, p < 0.001, Fig. 3).
Table 1 Baseline characteristics of the study population
Variable Control Group CAD Group P value
(n = 162) (n = 381)
Age (years) 55.41 ± 9.28 62.79 ± 9.52 <0.01
Male, n (%) 57(35%) 211(55%) < 0.01
Family history, n (%) 20(12%) 55(14%) 0.52
Smoking, n (%) 46(28%) 186(49%) < 0.01
DM, n (%) 25(15%) 139(36%) < 0.01
HT, n (%) 85(52%) 291(76%) < 0.01
HGB (g/L) 135.33 ± 15.87 136.53 ± 15.53 0.42
Platelet (109/L) 221.32 ± 51.31 211.14 ± 53.40 0.04
Leukocyte (109/L) 6.07(4.99–7.13) 6.60(5.60–7.70) < 0.01
Neutrophil (109/L) 3.42(2.95–4.41) 4.24(3.40–5.10) < 0.01
Monocyte (108/L) 3.02(2.51–3.62) 3.92(3.22–4.94) < 0.01
Lymphocyte (109/L) 1.95(1.49–2.29) 1.70(1.36–2.19) < 0.01
FBG (mmol/L) 5.35(4.93–5.88) 6.22(5.35–7.76) < 0.01
TC (mmol/L) 4.84 ± 1.10 4.99 ± 1.13 0.15
TG (mmol/L) 1.51(1.06–2.23) 1.51(1.13–2.30) 0.36
LDL (mmol/L) 2.65(2.12–3.25) 2.73(2.23–3.43) 0.29
HDL (mmol/L) 1.16(0.94–1.39) 1.07(0.92–1.30) 0.03
SCr (μmol/L) 71.34(59.27–83.51) 75.96(64.82–89.80) < 0.01
UA (μmol/L) 334.12 ± 93.41 335.56 ± 91.61 0.87
NLR 1.87(1.42–2.36) 2.47(1.86–3.34) < 0.01
MLR 0.16(0.13–0.21) 0.23 (0.17–0.30) < 0.01
Prior Medications
Aspirin, n (%) 133(82%) 320(84%) 0.59
Beta-blocker, n (%) 61(38%) 170(45%) 0.13
ACEI/ARB, n (%) 70(43%) 194(51%) 0.10
Stain, n (%) 129(80%) 317(83%) 0.32
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor
blocker, DM diabetes mellitus, FBG fasting blood-glucose, HDL high-density
lipoprotein, HGB Hemoglobin, HT hypertension, LDL low-density lipoprotein,
MLR Monocyte to lymphocyte ratio, NLR neutrophil to lymphocyte ratio, SCr
serum creatinine, TC total cholesterol, TG triglyceride, UA uric acid
Table 2 Multivariate logistic regression analysis to assess predictors
of CAD
Variable β Wald P value OR 95% CI
Age 0.09 35.29 < 0.01 1.09 1.06–1.12
Male 0.82 4.69 0.03 2.28 1.08–4.79
MLR 1.37 5.11 0.02 3.94 1.20–12.95
NLR 0.81 5.47 0.02 2.24 1.14–4.42–
HT 0.59 5.54 0.02 1.81 1.10–2.97
FBG 0.36 14.66 < 0.01 1.44 1.19–1.73
CI confidential interval, FBG fasting blood-glucose, HT hypertension, MLR
Monocyte to lymphocyte ratio, NLR neutrophil to lymphocyte ratio; OR
odds ratio
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Discussion
MLR calculated as a simple ratio between monocyte and
lymphocyte, has been evaluated as an inflammatory re-
sponse biomarker in various cancers and tuberculosis
[21–24], while there is still no report on the relationship
between MLR and coronary lesion severity. To the best
of our knowledge, our study is the first report to investi-
gate whether there is an association of MLR with coron-
ary lesion severity in CAD. In total, 543 patients were
enrolled in our retrospective study, MLR (OR: 3.94,
95%CI: 1.20–12.95) together with NLR, age, male, hyper-
tension, fasting blood glucose were proved to be inde-
pendent risk factors of CAD. In this study, we also
demonstrated that circulating MLR level was a predictor
of coronary lesion severity (OR: 2.05, 95%CI: 1.15–3.66),
with better performance compared with NLR in terms
of logistic analysis. Besides, there is no significant rela-
tionship observed between NLR and lesion severity in
CAD patients, which is different from previous studies
[18, 20].
Atherosclerosis is characterized as a chronic and lasting
inflammatory process of arteries, like other inflammatory
diseases, characterized by infiltration of immune cells, in-
cluding monocyte, neutrophils and lymphocyte [10]. The
pathogenesis and progression of atherosclerosis lesions is
a complex process in which multi-inflammatory factors
play a central role [26, 27]. Accumulations of monocytes
and monocyte-derived phagocytes are remarkable in the
Fig. 1 Diagnostic accuracy of circulating MLR in patients with CAD were analyzed by ROC curve; a scatter diagram; b ROC curve of MLR. MLR:
monocyte to lymphocyte ratio; CAD: coronary artery disease
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Age(years) 55.41 ± 9.28 61.35 ± 9.20 62.78 ± 9.08 66.76 ± 9.85 < 0.01
Male, n (%) 57(35%) 109(51%) 56(62%) 46(59%) < 0.01
Family history, n(%) 20(12%) 26(12%) 14(16%) 15(19%) 0.41
Smoking, n (%) 46(28%) 93(44%) 50(56%) 43(55%) < 0.01
DM, n (%) 25(15%) 60(28%) 45(50%) 34(44%) < 0.01
HT, n (%) 85(52%) 157(74%) 67(74%) 67(86%) < 0.01
HGB (g/L) 135.33 ± 15.87 136.52 ± 14.30 138.84 ± 17.09 133.88 ± 16.63 0.18
Platelet (109/L) 221.32 ± 51.31 215.01 ± 53.60 206.66 ± 57.82 205.73 ± 46.94 0.08
Leukocyte (109/L) 6.07(4.99–7.13) 6.41(5.36–7.50) 6.92(6.00–8.18) 6.67(5.80–8.08) < 0.01
Neutrophil (109/L) 3.42(2.95–4.41) 3.90(3.20–4.63) 4.73(3.81–5.49) 4.67(3.80–5.70) < 0.01
Monocyte (108/L) 3.02(2.51–3.62) 3.52(3.04–4.38) 4.24(3.36–4.92) 4.81(3.56–5.62) < 0.01
Lymphocyte (109/L) 1.95(1.49–2.29) 1.84(1.46–2.28) 1.70(1.37–2.06) 1.37(1.10–1.91) < 0.01
FBG (mmol/L) 5.35(4.93–5.88) 6.04(5.27–7.24) 6.74(5.53–9.41) 6.34(5.56–8.15) < 0.01
TC (mmol/L) 4.84 ± 1.10 5.03 ± 1.10 4.88 ± 1.19 5.04 ± 1.13 0.35
TG (mmol/L) 1.51(1.06–2.23) 1.57(1.17–2.30) 1.47(1.12–2.31) 1.42(1.04–2.19) 0.34
LDL (mmol/L) 2.65(2.12–3.25) 2.76(2.23–3.35) 2.57(2.09–3.44) 2.88(2.29–3.48) 0.40
HDL (mmol/L) 1.16(0.94–1.39) 1.09(0.92–1.29) 1.04(0.92–1.27) 1.15(0.90–1.31) 0.12
SCr (μmol/L) 71.34(59.27–83.51) 73.36(62.94–86.25) 79.35(65.35–92.30) 81.64(65.85–92.96) < 0.01
UA (μmol/L) 334.12 ± 93.41 331.93 ± 88.51 335.62 ± 88.79 345.44 ± 102.95 0.74
NLR 1.87(1.42–2.36) 2.09(1.64–2.77) 2.73(2.24–3.34) 3.37(2.50–4.75) < 0.01
MLR 0.16(0.13–0.21) 0.20(0.15–0.25) 0.23(0.19–0.31) 0.29(0.21–0.43) < 0.01
DM diabetes mellitus, FBG fasting blood-glucose, HDL high-density lipoprotein, HGB Hemoglobin, HT hypertension, LDL low-density lipoprotein, MLR Monocyte to
lymphocyte ratio, NLR neutrophil to lymphocyte ratio, SCr serum creatinine, TC total cholesterol, TG triglyceride, UA uric acid
Fig. 2 Comparison of MLR values according to the Syntax score. MLR: monocyte to lymphocyte ratio
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arterial wall, contributing to chronic inflammation
process and the formation, exacerbation and complica-
tions of atherosclerosis. Monocytes can recruit to the
artery wall, differentiate into macrophages and activate
the production of proinflammatory cytokines secretion,
matrix metalloproteinases, and reactive oxidative spe-
cies which play a key role in the initiation and forma-
tion, or rupture of atherosclerotic plaque [28]. And
monocytes phenotype modulation has become a specific
therapeutic target for the prevention and treatment of
cardiovascular diseases [29]. The lymphocyte represents a
potentially important immune cell in cardiovascular dis-
ease. Lymphocytopenia, because of increased lymphocytes
apoptosis, is a common hall mark of chronic inflammatory
status, which is thought to be a negative index of anti-
inflammation, post-infarct cardiac healing and remodel-
ing [30, 31]. Nunez et al reported that low lymphocyte
count was associated with the increased risk of myocar-
dial infarction or death through the analysis in 1030
patients [32]. In addition, low lymphocyte was found to
be reflective of impaired coronary microcirculation
which had been validated as a relevant pathogenetic
mechanism for CAD [33, 34]. High monocytes and low
lymphocytes were confirmed to be independent risk in-
dicators of cardiovascular diseases [16]. Therefore,
MLR integrating the risk of these two subtypes index
into a single risk factor may be a better risk factor of
coronary lesion severity. In our study, increased mono-
cyte and lower lymphocyte were found in CAD pa-
tients, which led to elevated MLR level. Moreover, our
study suggested that an MLR > 0.18 predicted CAD
with a sensitivity of 69.03% and specificity of 64.81%.
Syntax score has been applied to evaluate the risk strati-
fication of CAD. Several Trials have demonstrated that
patients with a relatively high Syntax score have worse
cardiovascular outcomes [6–8]. In our study, MLR
level was positively related to the Syntax score (r =
0.437, p < 0.001), which reflected that patients with
relatively higher MLR might have more severe coron-
ary stenosis and MLR could be helpful in predicting
the severity of the lesion. Based on ROC curve analysis,
MLR > 0.25 predicted severe lesion with a sensitivity of
Table 4 Result of ordinal logistic regression analysis
Variable β Wald P value OR 95% CI
Age 0.06 41.03 < 0.001 1.06 1.04–1.08
Smoke 0.67 8.3 0.004 1.95 1.24–3.08
DM 0.43 4.06 0.044 1.54 1.01–2.36
HT 0.61 10.18 0.001 1.85 1.27–2.69
FBG 0.14 9.61 0.002 1.15 1.05–1.25
MLR 0.72 5.93 0.015 2.05 1.15–3.66
DM diabetes mellitus, FBG fasting blood-glucose, HT hypertension, MLR monocyte
to lymphocyte ratio
Fig. 3 ROC curve for the Diagnostic accuracy of MLR in severe atherosclerosis. MLR: monocyte to lymphocyte ratio
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78.49% and specificity of 60.26%, which supported MLR
could be used to identify severe lesion.
In conclusion, we consider that MLR, a widely available,
inexpensive, and robust inflammatory biomarker, could be
helpful to predict CAD and evaluate the severity of coron-
ary lesion.
Study limitations
The major limitation of our present research is the limited
study population, and a single center study, other than
multiple centers and cross-sectional research. Besides,
coronary angiography was the only means to evaluate cor-
onary lesion. Some limitations existing in angiography in-
clude the inherently limited ability to identify only surface
morphology and its inability to subsurface morphology
and internal plaque composition. Other inflammatory
markers such as C reactive protein, interleukin-6 and
tumor necrosis factor-alpha, were not evaluated in the
study. Thus, further efforts on intravascular ultrasound
and optical coherence tomography may provide more use-
ful suggestions on the evaluation of coronary lesion.
Conclusions
To our best knowledge, our study is the first report on the
relationship between MLR and coronary lesion severity.
We found that MLR was a risk factor of atherosclerosis,
and can be a predictor for the severity of the lesion rather
than NLR. Also MLR was significantly correlated with
Syntax score. Therefore we consider that patients with
CAD who have a higher MLR also have more atheroscler-
osis involvement and we also suggest a preprocedural
MLR, a widely available, inexpensive, and robust inflam-
matory biomarker, could be helpful for cardiac risk
stratification.
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